Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 20/20 | 0.48 |
| ▸ | MMP2 | P08253 | 3/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745289 | 1.00 | ADAMTS5 (0.48) | ADAMTS5MMP2ADAM17MMP13MMP14 | |
| SCHEMBL29250249 | 1.00 | ADAMTS5 (0.48) | ADAMTS5MMP2ADAM17MMP13MMP14 | |
| SCHEMBL29250259 | 1.00 | ADAMTS5 (0.48) | ADAMTS5MMP2ADAM17MMP13MMP14 | |
| SCHEMBL23727429 | 1.00 | ADAMTS5 (0.48) | ADAMTS5MMP2ADAM17MMP13MMP14 | |
| SCHEMBL23745388 | 1.00 | ADAMTS5 (0.48) | ADAMTS5MMP2ADAM17MMP13MMP14 | |
| SCHEMBL29835201 | 0.91 | ADAMTS5 (0.47) | ADAMTS5MMP2ADAM17MMP13MMP14 | |
| SCHEMBL29835173 | 0.91 | ADAMTS5 (0.47) | ADAMTS5MMP2ADAM17MMP13MMP14 | |
| SCHEMBL29835218 | 0.91 | ADAMTS5 (0.47) | ADAMTS5MMP2ADAM17MMP13MMP14 | |
| SCHEMBL23745213 | 0.91 | ADAMTS5 (0.54) | ADAMTS5MMP2ADAM17MMP13MMP14 | |
| SCHEMBL23745335 | 0.91 | ADAMTS5 (0.54) | ADAMTS5MMP2ADAM17MMP13MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD (CN) | 2024-09-12 | — | — | US | disclosed |
| CN-115052596-B | ADAMTS inhibitor, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4100005-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2022-12-14 | — | — | EP | disclosed |
| CN-115052596-A | ADAMTS inhibitor, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2021158626-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | ADAMTS5, ADAMTS4, ADAMTS1 | ADAMTS5 1/4885MMP2 30/4885ADAM17 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.